Real-world evidence in action: A validated survival endpoint and genomic predictors of T-DXd response

Two peer-reviewed studies, one de-identified real-world database. The first, led by Tempus scientists, validates the database’s real-world survival endpoint against the U.S. gold standard. The second, conducted with Eisai Inc., uses the same data to surface genomic correlates of therapy response.